Interchim Inc
sublayer sublayer sublayer sublayer
sublayer sublayer sublayer sublayer

Purification Instruments, Columns and Modules

Strategic Partners



The Empiriko-Interchim partnership fully leverages Empiriko’s game-changing chemosynthetic liver technology (Biomimiks™) and Interchim’s innovative instrumentation and expertise in the field of chromatography. Interchim’s PuriFlash® and Prep HPLC columns are linked to a mass spectrometer which allows near real-time product separation and structure elucidation of purified compounds; these “smart devices” are ideally suited for taking full advantage of Empiriko’s Biomimiks™ technology. Together, our technology will accelerate the delineation of metabolism profiles, enable prediction and scale-up of products, and offer scientists a valuable tool for rapid separation and quantification of products.


Empiriko Overview


Empiriko is a Clinical Intelligence Technology (CIT) company that takes a unique, holistic approach to drug discovery, development and patient outcomes by combining scientific research and clinical observations with leading-edge technologies and advanced analytics. To achieve a higher level of predictive power, Empiriko has designed in vitro and ex vivo biomimetic systems – Biomimiks™ – that function as “chemosynthetic livers,” emulating the in vivo metabolism mediated by cytochromes P450 to generate and predict oxidative metabolic profiles of drugs. Our chemistry-based technology significantly reduces the time and cost associated with isolating and identifying drug metabolites using liver slices and bodily fluids extracted from animals.


Biomimiks™ solutions are used to:


  • Prepare isolable quantities of drug metabolites in non-aqueous conditions; synthesize on multi-gram scale.
  • Correlate isolated metabolites with those obtained from clinically isolated phenotypes.
  • Design an efficient method for the systematic preparation and identification of the entire spectrum of metabolites from a chosen drug.
  • Detect pharmaceutical products and their metabolites from serum, blood and urine.

Applying Biomimiks™ solutions, scientists can now reduce the attrition rate of NCEs by conducting metabolism studies on a range of compounds, generating quantitative measures of toxicity and reducing the cost of animal experimentation and necessity of animal sacrifice. In addition, clinicians can dynamically measure a patient’s response (drug-to-drug interactions, dosing levels and regimens) to a spectrum of drugs and incorporate the results into more effective diagnoses and patient treatment.